CCS Inc., Kyoto, Japan) installed on the ceiling
the composition comprises a cannabinoid selected from the group consisting of cannabidiol (CBD), Cannabinol (CBN), Cannabigerol (CBG), Cannabichromene (CBC), Cannabicyclol (CBL), Cannabivarin (CBV), Tetrahydrocannabivarin (THCV), Cannabidivarin (CBDV), Cannabichromevarin (CBCV), Cannabigerovarin (CBGV), Cannabigerol Monomethyl Ether (CBGM), Tetrahydrocannabinol (THC), cannabidiolic acid (CBDA), tetrahydrocannabinolic acid (THCA), Cannabichromenic acid (CBCA), cannabigerolic acid (CBGA), tetrahydrocannabivari the antioxidant is selected from the group consisting of: L-ergothioneine, butylated hydroxytolune (BHT), butylated hydroxy anisole (BHA), tert-Butylhydroquinone (TBHQ), pyrogallol, propylgallate, N,N-Di-sec-butyl-p- phenylenediamine, coenzyme Q10, astaxanthin, ellagic acid, picrocrocin, lycopene, lutein/zeaxanthin, lutein, zeaxanthin, quercetin, vitamin C, IP-6, beta-carotene, epicatechin, ECGC-epigallocatechin gallate, safranal, proanthocyanidins, resveratrol, vitamin E, melatonin, and mitoQ
Coupled to biochemical evidence, the presence of these non-catalytic L-sites in GSTUs and GSTFs suggest that at least some of them should function in the transport of endogenous metabolites (Dixon et al., 2011a)
The unique anatomy of the nose-brain interface facilitates direct drug transport via the olfactory and trigeminal pathways to the brain, bypassing the bloodbrain barrier
